- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07840976
Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL (Ph+ ALL-2026)
A Prospective, Umbrella, Phase 2 Study of Immunotargeted Agents Combined With Low-Dose Chemotherapy in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia
This is a prospective, open-label, single-arm, umbrella phase 2 clinical trial enrolling 22 adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia (ALL).
As an umbrella trial, all patients share the same target disease (newly diagnosed Ph+ B-ALL) and receive a uniform induction backbone consisting of multi-targeted immunotherapy, targeted therapy, and reduced-intensity chemotherapy. After induction, patients are stratified and assigned to two distinct consolidation pathways based on clinical condition, performance status, resource availability, and patient preference:
Pathway A: Consolidation with CD19-directed CAR-T cell therapy to achieve deep molecular remission; Pathway B: Consolidation with sequential immunochemotherapy to maximize minimal residual disease (MRD) clearance.
A backup chemotherapy backbone is provided for patients ineligible for antibody therapy. All patients, regardless of consolidation pathway, proceed to a unified long-term maintenance regimen. The primary endpoint is the complete molecular remission (CMR) rate after one cycle of induction therapy. MRD is monitored longitudinally by flow cytometry, quantitative PCR, and immune repertoire sequencing. Safety is evaluated per NCI CTCAE version 5.0.
Studieoversikt
Status
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Ying Wang, MD, PhD
- Telefonnummer: +86 22-23608095
- E-post: wangying1@ihcams.ac.cn
Studiesteder
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 301600
- Chinese Academy of Medical Sciences Hospital of Hematology (Chinese Academy of Medical Sciences Institute of Hematology)
-
Ta kontakt med:
- Runxia Gu
- Telefonnummer: +86-22-23608095
- E-post: gurunxia@ihcams.ac.cn
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years
- Newly diagnosed, previously untreated Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL) confirmed by cytogenetics and/or molecular testing
- Leukemic blasts expressing CD22
- Adequate organ function (renal, hepatic, cardiac)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Life expectancy ≥ 3 months
- Written informed consent obtained prior to any study-related procedures
Exclusion Criteria:
- Prior systemic anti-leukemic therapy, including chemotherapy, targeted therapy, or immunotherapy
- History of chronic myeloid leukemia (CML) or other hematologic malignancies
- Central nervous system (CNS) leukemia or extramedullary disease at diagnosis
- Uncontrolled active infection or severe comorbidities
- HIV positivity or known hepatitis B/C infection with active viral replication
- Pregnant or breastfeeding
- Inability to comply with study procedures or follow-up requirements
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Immunotargeted Therapy + Low-Dose Chemotherapy Arm
All patients receive a uniform induction therapy backbone combining targeted therapy, immunotherapy, and reduced-intensity chemotherapy. After induction, patients are stratified into two consolidation pathways based on clinical status: 1) CD19 CAR-T cell therapy; 2) sequential immunochemotherapy. All patients proceed to a unified long-term maintenance regimen. |
Third-generation tyrosine kinase inhibitor (TKI) targeting BCR::ABL1, administered orally daily as part of induction, consolidation, and maintenance therapy. BCL-2 inhibitor administered orally daily during induction and consolidation cycles to enhance leukemic cell apoptosis. Anti-CD22 antibody-drug conjugate (ADC) administered intravenously during induction and consolidation therapy. CD19/CD3 bispecific T-cell engager (BiTE) administered as continuous intravenous infusion during consolidation therapy. Autologous CD19 CAR-T cell therapy administered as a single intravenous infusion as optional consolidation therapy for eligible patients. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Complete Molecular Remission (CMR) Rate After 1 Cycle of Induction Therapy
Tidsramme: At the end of Cycle 1 (each cycle is 28 days, approximately 4 weeks from enrollment)
|
The proportion of patients achieving complete molecular remission (CMR), defined as undetectable BCR::ABL1 transcript by quantitative PCR (BCR::ABL1/ABL1 ratio < 0.001%), after 1 cycle of induction therapy. |
At the end of Cycle 1 (each cycle is 28 days, approximately 4 weeks from enrollment)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
3-Month Complete Remission (CR)
Tidsramme: 3 months after study enrollment
|
3 months after study enrollment
|
|
|
3-Month MRD Negativity Rates
Tidsramme: 3 months after study enrollment
|
3 months after study enrollment
|
|
|
2-Year Overall Survival (OS)
Tidsramme: 2 years after the last patient enrollment
|
OS is defined as the time from study enrollment to death from any cause. |
2 years after the last patient enrollment
|
|
2-Year Disease-Free Survival (DFS)
Tidsramme: 2 years after the last patient enrollment
|
DFS is defined as the time from study enrollment to disease relapse or death from any cause. |
2 years after the last patient enrollment
|
|
2-Year Event-Free Survival (EFS)
Tidsramme: 2 years after the last patient enrollment
|
EFS is defined as the time from study enrollment to first occurrence of predefined adverse events, disease progression or death. |
2 years after the last patient enrollment
|
|
Incidence of Treatment-Related Adverse Events (TRAEs)
Tidsramme: From study enrollment to 60 days after the last treatment
|
Number and severity of adverse events graded according to NCI CTCAE version 5.0. |
From study enrollment to 60 days after the last treatment
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Aminosyrer, peptider og proteiner
- Proteiner
- Karbohydrater
- Glykosider
- Antistoffer, monoklonalt, humanisert
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Aminoglykosider
- Calicheamicins
- Inotuzumab Ozogamicin
- Venetoclax
- Blinatumomab
- Olverembatinib
Andre studie-ID-numre
- IIT2026061
- IIT2026061-EC-1 (Annen identifikator: Ethics Committee of Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .